An encouraging bit on this in the article above is if they can trick a tumor into being vulnerable to PARP inhibs, might be more broadly helpful. Here's a cure-ious bit in CURE about Inaparib:
http://www.curetoday.com/index.cfm/f...rticle_id/1713
Quote:
|
When responses from newly diagnosed women were separated out from those of previously treated women, the numbers suggested another story. For reasons yet unknown, women with one to two prior treatments for advanced breast cancer seemed to improve on the drug when looking at both progression-free survival (4.2 months versus 2.9 months) and overall survival (10.8 months versus 8.1 months).
|
Maybe the pretreatment induces changes to the cells that make them them PARP inhib vulnerable.